Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
36,000,977
-
Share change
-
-816,028
-
Total reported value
-
$244,796,872
-
Put/Call ratio
-
536%
-
Price per share
-
$6.80
-
Number of holders
-
124
-
Value change
-
-$13,671,741
-
Number of buys
-
84
-
Number of sells
-
36
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q2 2021
As of 30 Jun 2021,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
124 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,000,977 shares.
The largest 10 holders included
TRV GP II, LLC, PFM Health Sciences, LP, TRV GP III, LLC, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., ORBIMED ADVISORS LLC, CITADEL ADVISORS LLC, VANGUARD GROUP INC, DIMENSIONAL FUND ADVISORS LP, and FMR LLC.
This page lists
124
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.